Compugen Sets KOL Event for Ovarian Cancer Drug COM701, Unigen Platform Update
Event summary
- Compugen to host virtual KOL event on October 5, 2026, featuring Dr. Oladapo Yeku to discuss COM701 in ovarian cancer.
- Interim analysis of MAIA-ovarian trial expected to deliver median progression-free survival data by Q1 2027.
- Unigen™ platform update to highlight expanded AI/ML capabilities for novel target discovery.
- COM701, a potential first-in-class anti-PVRIG antibody, currently in Phase 1 clinical studies.
The big picture
Compugen's event underscores the growing intersection of AI-driven drug discovery and immuno-oncology, with COM701 representing a potential breakthrough in ovarian cancer treatment. The focus on adaptive trial designs and platform updates reflects broader industry trends toward data-driven, efficient clinical development. Success here could validate Compugen's computational approach and attract further partnerships.
What we're watching
- Clinical Validation
- Whether COM701 can demonstrate meaningful efficacy in the MAIA-ovarian trial to position as a first-in-class therapy.
- Platform Scalability
- The pace at which Unigen™ can expand its target discovery capabilities to fuel Compugen's pipeline.
- Partnership Dynamics
- How collaborations with AstraZeneca and Gilead will impact Compugen's commercialization strategy.
Related topics